Health
CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma – Medical Xpress
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the…
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine. The findings represent the longest follow-up published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory…
-
General14 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News23 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News21 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
Noosa News15 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial